EMA ICH M12 on drug interaction studies (Draft Guidance)

July 21, 2022

Draft Guidance

July 2022

This guideline provides recommendation to promote a consistent approach in designing, conducting, and interpreting enzyme- or transporter-mediated in vitro and clinical pharmacokinetic drug-drug interaction (DDI) studies during the development of a therapeutic product. These aspects in general apply to the development of small chemical molecules. DDI evaluation of biologics is only covered briefly, with focus on monoclonal antibodies and antibody-drug conjugates. Guidance is provided on how to investigate interactions mediated by inhibition or induction of enzymes or transporters, both in vitro and in vivo, and on how to translate the results to appropriate treatment recommendations.

The guideline also includes recommendations on how to address metabolite-mediated interactions. The use of model-based data evaluation and DDI predictions are also covered.

Keywords: Interaction, metabolism, inhibition, induction, transport, enzyme, transport protein, transporter, absorption, physiologically based pharmacokinetic (PBPK), DDI; drug-drug interactions; pharmacokinetics; PK

Download Draft Guidance

Interested in learning more? Contact us today to find out how we can help with your global regulatory needs.


Agency Alerts FDA Guidance

April 14, 2022

FDA publishes draft guidance for industry: Considerations for Waiver Requests for pH Adjusters in Generic Drug Products Intended for Parenteral, Ophthalmic, or Otic Use

On April 13, 2022, FDA published a new draft guidance for industry entitled “Considerations for Waiver Requests for pH Adjusters in Generic Drug Products Intended for Parenteral, Ophthalmic, or Otic...

Read the Full Article
Agency Alerts General Regulatory

September 30, 2015

FDA Releases Draft Guidance Regarding the Use of Investigational Tobacco Products

Currently, there are no regulations specifically regarding investigational tobacco products. As such, at this time they are not exempt from requirements stated in the FD&C Act. Last week, FDA...

Read the Full Article

January 20, 2016

Cybersecurity in Medical Devices: Definitions from FDA's Draft Guidance

Compensating Controls: “A safeguard or countermeasure, external to the device, employed by a user in lieu of, or in the absence of sufficient controls that were designed in by a device manufacturer,...

Read the Full Article